奥扎格雷钠治疗短暂性脑缺血发作的临床观察及对预后的影响

The Therapeutic Effect and Prognosis of Sodium Ozagrel on Treatment of Transient Ischemic Attack

目的探讨奥扎格雷钠治疗短暂性脑缺血发作的疗效及安全性。方法将70例短暂性脑缺血发作患者随机分为治疗组与治疗对照组,治疗组35例应用奥扎格雷钠注射液80mg溶于0.9%氯化钠注射液250mL中静脉滴注,早晚各1次,连用14天,同时加用川芎嗪80mg,1次/d静滴,连用14天;治疗对照组应用川芎嗪80mg,1次/d静滴,连用14天。两组患者同时应用低分子肝素钙5000u,皮下注射,2次/d,连用14天,阿司匹林100mg,1次/d。所有短暂性脑缺血发作患者及正常对照组行颈动脉超声检测内膜—中膜厚度及斑块。观察治疗组与治疗对照组患者治疗前后血小板聚集率和纤维蛋白原水平,并观察30天内脑血管事件发生率。结果短暂性脑缺血发作患者与正常对照组内膜—中膜厚度分别为1.30±0.15mm和0.88±0.21mm,斑块检出率分别为40.3%和8.7%,差异有显著性(P<0.01)。两个治疗组血小板聚集率和纤维蛋白原水平治疗后比较差异有显著性(P<0.05),脑血管事件发生率差异也有统计学意义(P<0.05)。结论奥扎格雷钠治疗短暂性脑缺血发作安全有效。

Aim To evaluate the therapeutic effect of sodium ozagrel on treatment of transient ischemic attack （TIA）, Methods 70 cases of TIA patients were allocated randomly into treatment group and treated control group （ 35 cases in every group）. The treatment group was given 80 mg of sodium ozagrel intravenously twice a day and Ligustrazine 80 mg intravenously once a day, the treated control group was given 80 mg Ligustrazine once a day, both groups were given 5 000 u low molecular weigh heparin subcutaneously twice a day and 100 nag asprin once a day. Carotid internal-media thickness （IMT） and arterial plaque of all patients and normal controls were measured by carotid ultrasonography. The platelet aggregation rate and fibrinogen level were observed in both treatment groups before and after 14 d treatment. The cerebralvascular events were observed in 30 d. Results The difference of fibrinogen level and platelet aggregation rate in the treatment group was significant compared with the treated control group （ P 〈 0.05 ）. The difference of IMT and percentage ~f carotid arterial plaque in the 70 cases of TIA was significant compared with the normal controls （ P 〈 0.01 ）. Compared with the treated control group, the cerebralvascular events in the treatment group decreased （ P 〈 0.01 ）. Conduslon Sodium ozagrel is effective and safe in treatment of TIA and progress the prognosis.